Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05981976 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Drug Levels of Abatacept Converted From Drug Substance by Two Different Processes in Healthy Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 174
- Enrollment target
NCT05981976 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 174 participants.
The verdict
NCT05981976, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 174 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the relative absorption of abatacept in healthy participants following subcutaneous (SC) administration in which the drug substance is manufactured with the current or new process.
Interventions
- BIOLOGICAL Abatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2023-08-18 |
| Est. Completion | 2023-12-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05981976
The ClinicalTrials.gov registry entry for NCT05981976 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abatacept is the first listed.
NCT05981976 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05981976 about?
NCT05981976 is a clinical study titled "A Study to Evaluate the Drug Levels of Abatacept Converted From Drug Substance by Two Different Processes in Healthy Participants". The purpose of this study is to compare the relative absorption of abatacept in healthy participants following subcutaneous (SC) administration in which the drug substance is manufactured with the current or new process.
What is the current status of trial NCT05981976?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 174 participants. The study started on 2023-08-18. Estimated completion is 2023-12-14.
What interventions are being tested in trial NCT05981976?
The interventions under investigation include: Abatacept (BIOLOGICAL).
Who is sponsoring clinical trial NCT05981976?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.